Albumin industry launches global promotionBMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7234.533 (Published 26 February 2000) Cite this as: BMJ 2000;320:533
All rapid responses
Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles or when it is brought to our attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not including references and author details. We will no longer post responses that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
We read with interest the news article (BMJ 2000; 320: 533)
concerning our albumin initiative and would like to comment, as many of
the statements require clarification.
First, it is important to note that albumin has an excellent safety
record. The safety and efficacy of albumin is recognized worldwide, with
over fifty years of use. Albumin is used in a wide range of patients for
various conditions including severe burns, shock, trauma and other life-
Second, we respectfully disagree with the findings of the Cochrane
Group report referenced in this article. Others share this view. Many
respected scientists and physicians have criticized the report, raising
serious questions about the validity of its findings (see BMJ 1998:317:882
-886). Albumin is a life-saving medicine with a well-documented safety
record. It will continue to play an important role in the treatment of
critically ill patients.
Finally, we would like to clarify the purpose and scope of the
association's albumin initiative. The Plasma Protein Therapeutics
Association (PPTA), formerly IPPIA and EAPPI, has initiated a scientific,
clinically driven programme to communicate the clinical benefits of
albumin to physicians, pharmacists and others. Through this initiative,
PPTA is supporting the development of clinical data related to albumin to
help encourage evidence-based medicine.
I appreciate this opportunity to provide additional clarification on
the association's efforts on albumin.
Jan M. Bult
Plasma Protein Therapeutics Association
Competing interests: No competing interests